This recommendation is unchanged from the 2017 ASCO Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer 3 and the 2021 joint Ontario Health (OH; Cancer Care Ontario)-ASCO Management ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.

This paper concentrates on designing the Solenoid valve fault diagnostic by using a combination of the STM32 microcontroller and the smart six-channel low-side switch TLE6232GP. Solenoid valves are ...

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) that target estrogen receptors through new mechanisms, highlighting modest ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 mutations before clinical progression, showing that early switching to ...

Since 2018, ASCO has advocated for passage of the Improving Seniors’ Timely Access to Care Act, which would streamline prior authorizations in Medicare Advantage and codify requirements for federal ...

The latest news from ASCO 2025 focusing on NSCLC including abstracts, features, and helpful conference information.

Improved survival seen with structured program in patients with resected colon cancer who have completed adjuvant chemo.

Updates in metastatic NSCLC from ASCO 2025 include data from TROPION-Lung02 on Dato-DXd, KRYSTAL-7 on first-line adagrasib, and zipalertinib from REZILIENT1, presented by Dr Jonathan Goldman.

ASCO 2025, prostate cancer, castration resistant prostate cancer (CRPC), DB‑1311/BNT324, antibody drug conjugate (ADC), Novel B7H3 antibody drug conjugate, PARP inhibitors.